Author:
Leboyer Marion,Foiselle Marianne,Tchitchek Nicolas,Tamouza Ryad,Lorenzon Roberta,Richard Jean-Romain,Arrouasse Raphaele,Le Corvoisier Philippe,Le Dudal Katia,Vicaut Eric,Ellul Pierre,Rosenzwajg Michelle,Klatzmann David
Reference52 articles.
1. Interleukin-2 improves amyloid pathology, synaptic failure and memory in Alzheimer’s disease mice;Alves;Brain,2017
2. Discovery of potent and highly selective inhibitors of GSK3b;An;Probe Reports from the NIH Molecular Libraries Program,2012
3. Baer, L., Blais, M.A. (Eds.), 2010. Handbook of Clinical Rating Scales and Assessment in Psychiatry and Mental Health. Humana Press, Totowa, NJ. doi: 10.1007/978-1-59745-387-5.
4. Induction of regulatory T cells and efficacy of low-dose interleukin-2 in systemic sclerosis: interventional open-label phase 1-phase 2a study;Barde;RMD Open,2024
5. Regulatory T cells require IL6 receptor alpha signaling to control skeletal muscle function and regeneration;Becker;Cell Metab.,2023